1
|
Balbo M, Barel M, Lottin-Divoux S, Jean D, Frade R. Infection of human B lymphoma cells by Mycoplasma fermentans induces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21). FEMS Microbiol Lett 2005; 249:359-66. [PMID: 16054780 DOI: 10.1016/j.femsle.2005.06.052] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2005] [Revised: 06/09/2005] [Accepted: 06/27/2005] [Indexed: 10/25/2022] Open
Abstract
Human cell lines are often infected by mycoplama strains. We have demonstrated that when infected by Mycoplasma fermentans, human B lymphoma cell proliferation increased strongly. These infected B cells expressed a p45 kDa protein which interacted with the intracellular domain of CD21, the EBV/C3d receptor. p45 analysis demonstrated that this is a new gene which encodes an elongation factor originating from Mycoplasma fermentans. p45 interaction with CD21 was specific, there being no interaction with CD19. This is the first demonstration that Mycoplasma fermentans, in infecting human B cells, generates a p45 Mycoplasma component that interacts with CD21, which is involved in B cell proliferation.
Collapse
Affiliation(s)
- Michelle Balbo
- INSERM U.672 (ex U.354), Immunochimie des Régulations Cellulaires et des Interactions Virales, Bâtiment G8, Campus 1, Génopole d'Evry, 5 rue Henri Desbruères, 91030, EVRY Cedex, France
| | | | | | | | | |
Collapse
|
2
|
Lottin-Divoux S, Jean D, Le Romancer M, Frade R. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav. Cell Signal 2005; 18:1219-25. [PMID: 16289966 DOI: 10.1016/j.cellsig.2005.10.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2005] [Revised: 09/30/2005] [Accepted: 10/03/2005] [Indexed: 10/25/2022]
Abstract
It is well established that CD21 activation on human B cell surface triggers B cell proliferation. We previously demonstrated that CD21 activation also triggers tyrosine phosphorylation of two components, p95 and p120, both interacting with SH2 domains of the p85 subunit of PI 3-kinase. We successively identified p95 as the nucleolin and the first signal transduction pathway specifically triggered by CD21 activation, i.e.: pp60Src activation, tyrosine phosphorylation of p95 nucleolin, its interaction with SH2 domains of p85 subunit and PI 3-kinase activation, followed by AKT-GSK-3 activations. We herein identified the p120 component as the protooncoprotein Cbl and the first steps associated to its activation. First, CD21 activation triggered Cbl tyrosine phosphorylation, which required c-Src kinase but not PI 3-kinase or Syk kinase activities. Involvement of Src kinase in this step was supported by inhibition of Cbl phosphorylation and its interactions with other components when cells were either preincubated with specific Src inhibitor or transfected with dominant-negative c-Src form. Second, once tyrosine phosphorylated, Cbl interacts with SH2 domains of p85 subunit, SH2 domains of Crk-L and with tyrosine phosphorylated Syk kinase. The third and unexpected feature was to found that, at the contrary of BCR or of CD19 (herein also analyzed for the first time), CD21 activation triggers dissociation of Cbl-Vav complex. Thus, these results provide the first molecular basis of a new signal transduction pathway specifically triggered by CD21 activation.
Collapse
Affiliation(s)
- Séverine Lottin-Divoux
- INSERM U.672 (ex U.354), Immunochimie des Régulations Cellulaires et des Interactions Virales, Bâtiment G8, Campus 1, 5 rue Henri Desbruères, Génopole d'Evry, 91030, EVRY Cedex, France
| | | | | | | |
Collapse
|
3
|
Barel M, Balbo M, Le Romancer M, Frade R. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively. Eur J Immunol 2003; 33:2557-66. [PMID: 12938232 DOI: 10.1002/eji.200324059] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We previously demonstrated that CR2 activation on human B lymphocyte surface specifically triggered tyrosine phosphorylation of the 95-kDa nucleolin, this leading to its binding on SH2 domains of p85 sub-unit of PI 3-kinase and to activation of this enzyme. The specificity of CR2 pathway was clearly demonstrated as neither CD19 nor BCR could induce tyrosine phosphorylation of nucleolin in normal B lymphocytes. These data led us to investigate herein additional molecular events, which were triggered by CR2 activation, upstream and downstream to PI 3-kinase activation. Upstream, we demonstrated that pp60src, a tyrosine kinase of the src family, was involved in tyrosine phosphorylation of nucleolin, while syk tyrosine kinase was not. We also demonstrated a direct protein-protein interaction of pp60src with nucleolin in a CR2-dependent and CD19-independent pathway. Downstream, we demonstrated that CR2 activation also triggered Akt and GSK3 enzyme activation, this pathway being under the control of pp60src tyrosine kinase activation. These regulatory functions of activated CR2 were specific as independent of syk tyrosine kinase and of CD19 and BCR activation. Thus, CR2 activation recruits a specific mechanism to activate PI 3-kinase and its subsequent pathways, this mechanism being different to those recruited by CD19 and BCR.
Collapse
Affiliation(s)
- Monique Barel
- Immunochimie des Régulations Cellulaires et des Interactions Virales, INSERM U.354, Evry, France.
| | | | | | | |
Collapse
|
4
|
Barel M, Le Romancer M, Frade R. Activation of the EBV/C3d receptor (CR2, CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 166:3167-73. [PMID: 11207269 DOI: 10.4049/jimmunol.166.5.3167] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We previously demonstrated that CR2 activation on human B lymphocyte surface triggered tyrosine phosphorylation of a p95 component and its interaction with p85 subunit of phosphatidylinositol 3' (PI 3) kinase. Despite identical molecular mass of 95 kDa, this tyrosine phosphorylated p95 molecule was not CD19, the proto-oncogene Vav, or the adaptator Gab1. To identify this tyrosine phosphorylated p95 component, we first purified it by affinity chromatography on anti-phosphotyrosine mAb covalently linked to Sepharose 4B, followed by polyacrylamide gel electrophoresis. Then, the isolated 95-kDa tyrosine phosphorylated band was submitted to amino acid analysis by mass spectrometry; the two different isolated peptides were characterized by amino acid sequences 100% identical with two different domains of nucleolin, localized between aa 411--420 and 611--624. Anti-nucleolin mAb was used to confirm the antigenic properties of this p95 component. Functional studies demonstrated that CR2 activation induced, within a brief span of 2 min, tyrosine phosphorylation of nucleolin and its interaction with Src homology 2 domains of the p85 subunit of PI 3 kinase and of 3BP2 and Grb2, but not with Src homology 2 domains of Fyn and Gap. These properties of nucleolin were identical with those of the p95 previously described and induced by CR2 activation. Furthermore, tyrosine phosphorylation of nucleolin was also induced in normal B lymphocytes by CR2 activation but neither by CD19 nor BCR activation. These data support that tyrosine phosphorylation of nucleolin and its interaction with PI 3 kinase p85 subunit constitute one of the earlier steps in the specific intracellular signaling pathway of CR2.
Collapse
MESH Headings
- Antigens, CD19/metabolism
- B-Lymphocytes/enzymology
- B-Lymphocytes/metabolism
- B-Lymphocytes/virology
- Herpesvirus 4, Human/immunology
- Humans
- K562 Cells
- Lymphoma, B-Cell/enzymology
- Lymphoma, B-Cell/immunology
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/virology
- Membrane Proteins/metabolism
- Membrane Proteins/physiology
- Peptide Fragments/metabolism
- Phosphatidylinositol 3-Kinases/metabolism
- Phosphoproteins/metabolism
- Phosphorylation
- Phosphotyrosine/metabolism
- Protein Binding/immunology
- Proto-Oncogene Mas
- RNA-Binding Proteins/metabolism
- Receptors, Antigen, B-Cell/metabolism
- Receptors, Complement 3d/metabolism
- Receptors, Complement 3d/physiology
- Tumor Cells, Cultured
- Nucleolin
Collapse
Affiliation(s)
- M Barel
- Immunochimie des Régulations Cellulaires et des Interactions Virales, Centre Institut National de la Santé et de la Recherche Médicale, Paris, France
| | | | | |
Collapse
|
5
|
D'Addario M, Ahmad A, Morgan A, Menezes J. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases. J Mol Biol 2000; 298:765-78. [PMID: 10801347 DOI: 10.1006/jmbi.2000.3717] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Epstein-Barr virus (EBV) is a human herpesvirus that interacts with various immunocompetent cells that carry the EBV receptor (CD21/CR2). EBV binds to CR2 through its major envelope glycoprotein 350 (gp350). Previously we had demonstrated that EBV and other human herpesviruses are capable of modulating cytokine synthesis through the deregulated expression of cytokine genes interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-2 (IL-2). Here we show that, in contrast to infectious EBV, purified recombinant gp350 upregulates TNF-alpha gene expression in human monocyte/macrophages (M/M) as well as in a monocytoid cell line, U937. Our results also demonstrate that this increased expression is due to both enhanced transcription and stability of TNF-alpha mRNA in gp350-treated cells. The specificity of this effect is evidenced by the fact that pre-incubation of cells with anti-CR2 monoclonal antibody OKB7, which blocks binding of gp350 to CR2, inhibits the above mentioned effects of gp350. Furthermore, we demonstrate that activation of TNF-alpha by gp350 is mediated by NF-kappaB through signal transduction pathways involving PKC, PI3-K and tyrosine kinases. To our knowledge this is the first report describing the modulation of TNF-alpha gene expression by the EBV-gp350 molecule following its interaction with the viral receptor CR2 on cells of the monocytic lineage.
Collapse
MESH Headings
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Cells, Cultured
- Cyclic AMP Response Element-Binding Protein/metabolism
- Dactinomycin/pharmacology
- Half-Life
- Herpesvirus 4, Human/physiology
- Humans
- Monocytes/drug effects
- Monocytes/enzymology
- Monocytes/metabolism
- NF-kappa B/metabolism
- Phosphatidylinositol 3-Kinases/metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Protein Biosynthesis/drug effects
- Protein Kinase C/antagonists & inhibitors
- Protein Kinase C/metabolism
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Protein-Tyrosine Kinases/metabolism
- RNA Stability/drug effects
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Complement 3d/antagonists & inhibitors
- Receptors, Complement 3d/immunology
- Receptors, Complement 3d/metabolism
- Recombinant Proteins/antagonists & inhibitors
- Recombinant Proteins/genetics
- Recombinant Proteins/metabolism
- Recombinant Proteins/pharmacology
- Signal Transduction/drug effects
- Transcription, Genetic/drug effects
- Tumor Necrosis Factor-alpha/analysis
- Tumor Necrosis Factor-alpha/biosynthesis
- Tumor Necrosis Factor-alpha/genetics
- Tumor Necrosis Factor-alpha/metabolism
- U937 Cells
- Up-Regulation/drug effects
- Viral Matrix Proteins/antagonists & inhibitors
- Viral Matrix Proteins/genetics
- Viral Matrix Proteins/metabolism
- Viral Matrix Proteins/pharmacology
Collapse
Affiliation(s)
- M D'Addario
- Laboratory of Immunovirology Department of Microbiology and Immunology and Pediatric Research Center, University of Montreal, and Ste. Justine Hospital, 3175 Cote Ste. Catherine, Montreal, Québec, H3T 1C5, Canada
| | | | | | | |
Collapse
|
6
|
Bouillie S, Barel M, Frade R. Signaling Through the EBV/C3d Receptor (CR2, CD21) in Human B Lymphocytes: Activation of Phosphatidylinositol 3-Kinase via a CD19-Independent Pathway. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.1.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
We herein analyzed the regulation of phosphatidylinositol 3-kinase (PI 3-kinase) activity by CR2 activated on B lymphocyte cell surface. We demonstrated that CR2 activation triggered in vivo PI 3-kinase activity and interaction of PI 3-kinase p85 subunit with a tyrosine-phosphorylated p95 component. The specificity of PI 3-kinase activity was controlled using wortmannin and LY294002. CR2 activation did not trigger tyrosine phosphorylation of PI 3-kinase p85 subunit, but induced direct interaction of tyrosine phosphorylated p95 with the Src homology 2 domain of p85 subunit, as shown using glutathione-S-transferase fusion proteins. Despite identical molecular masses, immunoblotting analysis demonstrated that tyrosine-phosphorylated p95 that interacted in vivo and in vitro with p85 was neither CD19, the 95-kDa proto-oncogene vav, nor Gab1 (a 95-kDa adaptor molecule). Furthermore, p95 tyrosine phosphoprotein also expressed in K562A cells (CR2+ CD19− cells) interacted with Src homology 2 domain of PI 3-kinase p85 subunit after CR2 activation. Activated CR2 did not interact directly with p85 subunit or tyrosine-phosphorylated p95. This suggests the presence of an intermediate molecule between activated CR2 and tyrosine-phosphorylated p95, which may be 3BP2. In addition, in contrast to CD19 activation, CR2 activation did not trigger interaction of CD19 or Vav with PI 3-kinase p85 subunit or coprecipitation of PI 3-kinase activity with CD19. Together, these data clearly demonstrated that CR2 activation triggered in vivo PI 3-kinase activation through a pathway distinct from that triggered through CD19 activation.
Collapse
Affiliation(s)
- Sylvie Bouillie
- Immunochimie des Régulations Cellulaires et des Interactions Virales, Institut National de la Santé et de la Recherche Médicale, Unit 354, Centre INSERM, Hôpital Saint-Antoine, Paris, France
| | - Monique Barel
- Immunochimie des Régulations Cellulaires et des Interactions Virales, Institut National de la Santé et de la Recherche Médicale, Unit 354, Centre INSERM, Hôpital Saint-Antoine, Paris, France
| | - Raymond Frade
- Immunochimie des Régulations Cellulaires et des Interactions Virales, Institut National de la Santé et de la Recherche Médicale, Unit 354, Centre INSERM, Hôpital Saint-Antoine, Paris, France
| |
Collapse
|
7
|
Tolnay M, Tsokos GC. Complement receptor 2 in the regulation of the immune response. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 1998; 88:123-32. [PMID: 9714689 DOI: 10.1006/clin.1998.4552] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Antigens coated with split products of C3, the result of complement activation, are capable of crosslinking the complement receptor 2 (CR2, CD21) and the antigen receptor on the surface of B cells simultaneously. This dual recognition leads to increased cell proliferation and differentiation and enhanced antibody production. CR2 is also considered to be a regulator of the B cell response to antigen. In this review we summarize the biology of the CR2 and focus on its essential role in generating an effective B cell response to antigenic stimuli. The involvement of CR2 in the pathophysiology of infectious and autoimmune diseases is also discussed.
Collapse
Affiliation(s)
- M Tolnay
- Department of Clinical Physiology, Walter Reed Army Institute of Research, Washington, DC, 20307, USA
| | | |
Collapse
|